Withania somnifera (L.) Dunal — Ayurveda's foremost adaptogen, a robust shrub of the Solanaceae family whose steroidal withanolides modulate the HPA axis, suppress neuroinflammation, and confer multi-system resilience confirmed across multiple randomised controlled trials.
Withania somnifera is a woody shrub of the Solanaceae family producing a class of unique steroidal lactones — the withanolides — that structurally resemble endogenous steroid hormones. These compounds act pleiotropically, modulating the HPA stress axis, suppressing NF-κB-mediated inflammation, and exerting direct neuroprotective and antioxidant effects across multiple organ systems.
Withania somnifera is a robust, erect, semi-woody perennial shrub native to the Indian subcontinent. It grows to approximately 30–150 cm in height on arid, rocky terrain, and has been successfully cultivated across the Mediterranean basin, the Canary Islands, and South Africa. The stems are flexuous and bear ovate, sub-acute leaves that are hispid (covered in short stiff hairs) on their lower surface.
Flowers are small, greenish-yellow, and grouped in axillary clusters of 3 to 6. The calyx has 5 teeth that persist and enlarge after flowering, ultimately enclosing the ripe fruit in a papery orange-red husk — a characteristic of the Physalis-related genera within Solanaceae. The fruit itself is a small, brilliant red, pea-sized berry.
Name Etymology
The name "Ashwagandha" derives from the Sanskrit for "smell of horse" (ashwa = horse, gandha = odour), referring both to the characteristic smell of the fresh root and to the traditional belief that consuming the plant would confer the strength and vitality of a horse. The species epithet somnifera (Latin: "sleep-bearing") reflects its traditional sedative and hypnotic uses.
Misnomer Note
Ashwagandha is commonly — and incorrectly — called "Indian Ginseng." While both plants are classified as adaptogens, they belong to entirely different botanical families and have distinct phytochemical profiles. Withania somnifera is a Solanaceae; true ginsengs (Panax spp.) are Araliaceae.
Withania somnifera holds a pre-eminent position in Ayurvedic medicine, where it is classified as a Rasayana — a rejuvenating substance believed to promote longevity, enhance mental faculty, and confer resistance to disease and physical fatigue. Its documented use spans over 3,000 years across South Asian healing traditions, and it has subsequently been adopted in Arabic, North African, and African traditional systems.
Cited in foundational Ayurvedic texts as a Rasayana herb for promoting vitality, sexual function, memory, and resistance to disease. Used as a tonic for debility, emaciation, and nervous exhaustion in all age groups.
Arab physicians became interested in the plant's properties, and it entered the Unani medical tradition — the Graeco-Arabic system practised across the Islamic world — where it was used for its tonic and anti-inflammatory properties.
Used extensively in traditional African medicine, particularly in Morocco, for its tonic, anti-inflammatory, and febrifugal properties. The plant has been cultivated in the Mediterranean coastal regions for centuries.
The archetype withanolide, Withaferin A, was first isolated and characterised in 1965, marking the beginning of systematic pharmacological investigation. Since then, approximately 300 withanolides with an ergostane-based C-28 skeleton have been identified from the plant.
Ayurvedic Canon
"One of the most famous plants in Ayurvedic medicine — a Rasayana, a rejuvenator — whose name evokes the power of the horse."
A comprehensive overview by Singh et al. (2011) describes ashwagandha as one of the most important plants in Ayurveda, documenting its use across debility, nervous exhaustion, male infertility, arthritis, and cognitive decline — all areas now actively validated by modern clinical trials. [37]
The root is the primary medicinal part used in both traditional Ayurvedic preparations and modern standardised extracts. Leaves and berries are used in regional ethnomedicine.
The classical Ayurvedic form. The whole dried root is ground and typically consumed in warm milk with honey (ashwagandha ksheer). Dosage: 3–6 g of dried powder daily. Contains the full spectrum of alkaloids, withanolides, and saponins.
Modern concentrated extracts (e.g. KSM-66® full-spectrum, Sensoril®) standardised to a defined withanolide content (typically 2.5–5%). Used in most published RCTs at 300–600 mg/day. Provides a consistent, reproducible dose of key actives.
Root decoctions are used in traditional practice. Leaf extracts contain higher concentrations of Withaferin A (up to 1.6% dry weight) than roots, and are used topically or in research settings. Berries are used regionally in India and Morocco.
Dosages below are corroborated by published RCTs. Dosages refer to oral administration of root preparations. Always use under qualified healthcare supervision.
| Formulation | Indication | Dose | Frequency | Source |
|---|---|---|---|---|
| Dried root powder | General tonic / adaptogen | 3–6 g | Daily, with warm milk | Traditional use |
| Root extract (standardised) | Stress, anxiety, cortisol reduction | 300–600 mg | Daily for 8–12 weeks | [2] |
| Root extract (standardised) | Sleep quality improvement | 600 mg | Daily for ≥8 weeks | [11] |
| Root extract (standardised) | Cardiorespiratory endurance (athletes) | 600 mg | Daily for 8 weeks | [3] |
| Root extract (standardised) | Anxiety, depression (adjunct in schizophrenia) | 1,000 mg | Daily (RCT context only) | [24] |
The root of Withania somnifera contains a unique combination of steroidal lactones (withanolides), pyrazoline alkaloids, and esterified steroidal saponins not found in combination in any other plant family.
C-28 Steroidal Lactone Skeleton
Ergostane-based framework structurally analogous to endogenous steroid hormones; ~300 naturally occurring variants identified in the plant
Withaferin A — Archetype
First isolated 1965; the most extensively studied withanolide. Principal anti-inflammatory, antitumoral, and antifungal agent; inhibits IKKβ at Cys-179, blocking NF-κB activation
Withanolide A & D
Key neuroprotective withanolides; inhibit acetylcholinesterase and amyloid-β aggregation; modulate NMDA receptor expression
Sitoindosides VII–X
Glycowithanolide fraction responsible for a significant portion of the antistress and antioxidant activity documented in early pharmacological studies
One of the most potent plant adaptogens known; experimental rat models of chronic stress demonstrate significant reduction in adrenal hypertrophy and blood cortisol levels attributable to glycowithanolide fractions. [1] [2]
Double-blind RCTs document statistically significant reductions in anxiety scores (HAM-A, DASS-21, PSS) versus placebo, with a 2022 meta-analysis of 12 RCTs in 1,002 adults confirming the effect. [5] [22]
Reduces markers of the stress response including cortisol and DHEA; demonstrates sedative and hypnotic properties. Root extract (600 mg/day for ≥8 weeks) improves sleep quality and mental alertness, particularly in insomniacs. [4] [19]
A systematic review and meta-analysis found that ashwagandha root extract improves overall sleep quality, sleep onset latency, and mental alertness on rising, with insomniacs showing the greatest benefit at ≥600 mg/day for ≥8 weeks. [11]
Protects neuronal cells against β-amyloid toxicity, HIV-1 infection, and oxidative damage. Modulates oxidative stress, regulates neurotransmitter systems, improves neuronal plasticity, and promotes neurogenesis in the hippocampus. [12] [13] [14]
Improves memory, attention, and information processing in both healthy individuals and those with mild cognitive impairment. Improves general mental capacity and sleep quality in elderly subjects. Potential in Alzheimer's and Parkinson's disease via neuroprotective mechanisms. [10] [14] [15]
Glycowithanolides exert significant antioxidant activity, reducing lipid peroxidation and restoring free radical scavenging enzyme activity in stressed brain tissue (striatum, frontal cortex). Also decelerates cellular senescence in normal human fibroblasts. [7] [8] [9]
Withanolides suppress TNF-α, IL-1β, IL-6, and IL-12p40 production. Withaferin A inhibits NF-κB activation by targeting IKKβ at Cys-179. Anti-inflammatory and analgesic in gouty arthritis without gastric damage. [25] [26] [27]
Anxiolytic-antidepressant activity demonstrated in experimental models comparable to standard anxiolytic drugs. Reduces depressive and anxiety symptoms in schizophrenic patients. Increases serotonin levels when combined with piperine. [17] [21] [24]
Stimulates natural killer cell activity, promotes Th-1 immune polarisation, and recovers stress-depleted T-cell populations. Shifts immune response toward cellular immunity in models of immunosuppression. [6]
Glycowithanolides protect against iron-induced hepatotoxicity in animal models, reducing oxidative liver damage through antioxidant enzyme upregulation. [16]
Rectal application of root extract demonstrates anti-inflammatory and mucosal restorative activity in a TNBS-induced inflammatory bowel disease model, suggesting potential in ulcerative colitis and Crohn's disease. [28]
Withaferin A triggers apoptosis, inhibits invasion, and suppresses osteoclastogenesis via NF-κB suppression. Demonstrates antifungal and antitumoral activity. Preclinical only — no validated clinical cancer treatment indication. [27]
The alkaloid fraction lowers blood pressure. The plant additionally reduces total cholesterol levels. These properties support its traditional use in cardiovascular conditions, though robust human RCT evidence remains limited. [1]
Increases haematopoiesis (bone marrow blood cell production) and haemoglobin levels, as well as melanin in hair pigmentation. Supports its indication in anaemia — the root is a notable source of bioavailable iron.
Systematic review and Bayesian meta-analysis confirm improvements in cardiorespiratory endurance, muscle strength, and recovery in athletes and healthy adults. A 2025 systematic review of biopsychological effects further supports these findings. [34] [35]
Gemmotherapeutic (bud) extracts of Withania somnifera demonstrate cardioprotective effects in a model of chemically induced myocardial injury, mediated by upregulation of antioxidant enzymes: superoxide dismutase, catalase, and glutathione peroxidase. [36]
Traditional uses corroborated by preclinical data include diuretic, antirheumatic, and antiseptic activities. Withanolides are reported to inhibit uric acid crystal deposition relevant to gout pathophysiology without causing gastric ulceration. [26]
Glycowithanolides significantly attenuate haloperidol-induced tardive dyskinesia in rat models, suggesting a role in managing antipsychotic-induced movement disorders as a complementary agent. [20]
Molecular docking studies indicate Withanone and Withaferin A interact with SARS-CoV-2 TMPRSS2 and Mpro protease; Withanoside V and Somniferin are predicted Mpro inhibitors. These are in silico and zebrafish model findings only — no human clinical evidence for COVID-19 treatment. [29] [30] [31] [32] [33]
Strength of evidence varies; see evidence grade notes below.
Withanolides are steroidal molecules specific to certain Solanaceae genera (Withania, Physalis, Nicandra, Lycium, Datura), structurally analogous to human steroid hormones, which underlies their ability to modulate endocrine, immune, and neurological signalling. The mechanisms below are supported by multiple independent published sources; presumed or preclinical-only mechanisms are clearly noted.
The most established mechanism. Ashwagandha supplementation consistently reduces morning serum cortisol and ACTH levels in clinical trials, indicating suppression of hypothalamic-pituitary-adrenal axis hyperactivation under chronic stress. A 2024 dose-response RCT confirmed dose-dependent reductions in both cortisol and salivary α-amylase. Withaferin A is hypothesised to interact directly with glucocorticoid receptors in the brain, though this remains to be fully established in humans. [2] [18] [23]
Withaferin A inhibits the NF-κB signalling pathway by directly targeting cysteine-179 of IKKβ, the kinase responsible for phosphorylating and degrading IκBα, the NF-κB inhibitory protein. This prevents nuclear translocation of the p65/p50 NF-κB dimer, suppressing transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12p40), inducible nitric oxide synthase (iNOS), and COX-2. Withanolides also upregulate the cytoprotective Nrf2/HO-1 antioxidant pathway simultaneously. [27] [25]
Multiple independent reviews and mechanistic studies identify GABAergic activity as a key contributor to ashwagandha's anxiolytic and sleep-promoting effects. Constituents of the root modulate GABA-A receptor signalling, increasing inhibitory tone in the central nervous system — an effect mechanistically comparable to benzodiazepines but without the same pharmacokinetic risks. This GABAergic activity is clinically relevant: it can produce pharmacodynamic interactions with benzodiazepines and other CNS depressants. [19] [5]
Withanolide A inhibits acetylcholinesterase in the brain and reduces NMDA receptor expression (a mechanism relevant to excitotoxic memory loss). Withanamides A and C neutralise the cytotoxicity of β-amyloid protein through direct interaction. The glycowithanolide fraction reduces oxidative stress in the striatum and frontal cortex, restores scavenging enzyme activity, and promotes hippocampal neurogenesis — effects documented across multiple independent animal and cell-line studies. [12] [13] [14] [15]
Ashwagandha and its withanolides simultaneously downregulate the pro-inflammatory NF-κB pathway and upregulate the cytoprotective Nrf2/HO-1 pathway in microglial cells, providing a dual anti-inflammatory and antioxidant mechanism. Glycowithanolides reduce lipid peroxidation, restore superoxide dismutase and catalase activity, and decelerate replicative senescence in normal human fibroblasts. [7] [8] [9]
Clinical studies report increased testosterone and luteinising hormone (LH) concentrations in men following ashwagandha supplementation. The structural analogy between withanolides and endogenous steroid hormones may contribute to this effect, though the exact mechanism is not yet fully characterised. Clinically relevant: avoid in hormone-dependent prostate cancer due to the probable testosterone-raising effect. Increased estradiol has been observed in perimenopausal women within physiological norms. [2]
Withania somnifera has a well-established safety profile at therapeutic doses.